Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 11 Characteristics of recent clinical trials with liposomal amphotericin B in mono or combined therapy

From: Nanomedicine review: clinical developments in liposomal applications

ReferencesYearsPhaseDiseaseLFnDose
Cornely et al. (2017)2017IIIIFDAmBisome®2285 mg/kg
Romero et al. (2017)2017IIIVLAmBisome®1093 mg/kg/day for 7 days
AmBisome® + MA11210 mg/kg single dose + 20 mg Sb+5/kg/day for 10 days
Rahman et al. (2017)2017IIIVLAmBisome® + Mil1425 mg/kg + 17.5 mg/kg
AmBisome + Par1595 mg/kg + 150 mg/kg
AmBisome®15815 mg/kg
Miyao et al. (2016)2016IIRFNAmBisome®801 mg/kg
Wasunna et al. (2016)2016IIVLAmBisome® + SSG5110 mg/kg + 20 mg/kg/day
AmBisome® + Mil4910 mg/kg + 2.5 mg/kg/day
  1. IFD invasive fungal diseases, VL visceral leishmaniasis, RFN refractory febrile neutropenia, LF liposomal formulation